CLL-IPI characteristics of newly diagnosed patients with CLL (n = 314)
| Variable . | N (%) . |
|---|---|
| Age, y | |
| ≤65 | 125 (39.8) |
| >65 | 189 (60.2) |
| Binet stage | |
| A | 273 (86.9) |
| B/C | 41 (13.1) |
| B2M, mg/L | |
| ≤4.0 | 263 (85.9) |
| >4.0 | 43 (14.1) |
| Missing | 8 |
| IGHV status | |
| Mutated | 211 (67.4) |
| Unmutated | 102 (32.6) |
| Missing | 1 |
| del(17p) | |
| Absent | 284 (95.3) |
| Present | 14 (4.7) |
| Missing | 16 |
| TP53 | |
| Mutated | 21 (6.7) |
| Wild type | 293 (93.3) |
| CLL-IPI risk | |
| Low | 167 (57.4) |
| Intermediate | 87 (29.9) |
| High | 31 (10.7) |
| Very high | 6 (2.1) |
| Missing | 23 |
| Variable . | N (%) . |
|---|---|
| Age, y | |
| ≤65 | 125 (39.8) |
| >65 | 189 (60.2) |
| Binet stage | |
| A | 273 (86.9) |
| B/C | 41 (13.1) |
| B2M, mg/L | |
| ≤4.0 | 263 (85.9) |
| >4.0 | 43 (14.1) |
| Missing | 8 |
| IGHV status | |
| Mutated | 211 (67.4) |
| Unmutated | 102 (32.6) |
| Missing | 1 |
| del(17p) | |
| Absent | 284 (95.3) |
| Present | 14 (4.7) |
| Missing | 16 |
| TP53 | |
| Mutated | 21 (6.7) |
| Wild type | 293 (93.3) |
| CLL-IPI risk | |
| Low | 167 (57.4) |
| Intermediate | 87 (29.9) |
| High | 31 (10.7) |
| Very high | 6 (2.1) |
| Missing | 23 |
B2M, β2-microglobulin.